{"id":"W4387810553","doi":"10.1016/j.annonc.2023.09.2572","title":"1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Progressive disease; Atezolizumab; Gemcitabine; Chemotherapy; Cancer; Gastroenterology; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001054837,0.0005400134,0.001186764,0.0003026143,0.0002027371,0.0009288958,0.0003393953,0.000686719,0.001665692],"category_scores_gemma":[0.001198071,0.000282905,0.001834967,0.0005759194,0.0003273988,0.0006084038,0.000392021,0.001021348,0.0004015756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004753345,"about_ca_system_score_gemma":0.0004974486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00132967,"about_ca_topic_score_gemma":0.003019511,"domain_scores_codex":[0.9995573,0.0001986631,0.00002824386,0.00009014328,0.00006267011,0.00006291857],"domain_scores_gemma":[0.999424,0.0001414371,0.000174086,0.00005793407,0.00003623051,0.0001663913],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4110966,0.006577342,0.4694012,0.0007858591,0.01008355,0.0004161403,0.0001809084,0.001383682,0.007189574,0.0001960451,0.003795787,0.08889332],"study_design_scores_gemma":[0.09426035,0.07847912,0.8058981,0.000135916,0.01113247,0.0007692247,0.0002376821,0.0009636358,0.001690302,0.0003670576,0.006002099,0.00006408375],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945254,0.002936729,0.00006211614,0.0001988911,0.0000445971,0.00006259861,0.00130292,0.00001329219,0.0008535388],"genre_scores_gemma":[0.9924636,0.002010264,0.0001721287,0.000338865,0.0001025405,0.0000852784,0.003762107,0.00001060322,0.001054607],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001665692,"threshold_uncertainty_score":0.005578578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06656061876900553,"score_gpt":0.3792253383067788,"score_spread":0.3126647195377733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}